[Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases]. 1983

K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata

Serum levels of complement components(cc), whole complement activity (CH 50), and circulating immune complexes (IC) were measured in 41 patients with neoplastic diseases. The level of cc was higher than in healthy controls; the levels of C1q, C1INA, C4, C3c, C3ACT, C5, and C9 were statistically higher. In patients with lung cancer, the levels of cc were correlated with the clinical stage as well as the performance status. Both the IC serum level and the incidence of high serum IC levels in lung cancer were higher in stage III and IV than in stage I and II. Serum CH 50 was higher than in healthy controls, but not correlated with the clinical stage.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003166 Complement Activating Enzymes Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways. Activating Enzymes, Complement,Enzymes, Complement Activating
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003174 Complement C1 Inactivator Proteins Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits. Complement 1 Esterase Inhibitors,Complement C1 Inactivating Proteins,Complement C1 Inhibiting Proteins,Complement C1 Inhibitor Proteins,Complement C1r Protease Inhibitor Proteins,Complement C1s Esterase Inhibitor Proteins,Complement Component 1 Inactivator Proteins
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5

Related Publications

K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1984, Plucne bolesti : casopis Udruzenja pneumoftiziologa Jugoslavije = the journal of Yugoslav Association of Phthisiology and Pneumology,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1984, Annales de biologie clinique,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
April 1991, Indian journal of pathology & microbiology,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1987, ORL; journal for oto-rhino-laryngology and its related specialties,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1980, Oncology,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1983, Voprosy onkologii,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
August 1983, The American Journal of dermatopathology,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
July 1981, Alergia,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
September 1981, Journal of clinical & laboratory immunology,
K Takada, and M Morishita, and T Sugiura, and M Suzuki, and Y Torii, and K Ichimura, and H Hashigami, and K Toshikawa, and Y Ina, and M Yamamoto, and A Oyama, and A Urata
January 1981, Terapevticheskii arkhiv,
Copied contents to your clipboard!